Drug Profile
DCB 0703
Alternative Names: Adjuvanted nasal spray influenza vaccine; DCB-0703; LT-Flu - Development Center for Biotechnology; LT-Flu vaccineLatest Information Update: 02 Jan 2023
Price :
$50
*
At a glance
- Originator Development Center for Biotechnology
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 02 Jan 2023 DCB 0703 is still in phase-II clinical trials for Influenza virus infections (Prevention) in USA (Intranasal) (Development Center for Biotechnology pipeline, January 2023)
- 30 Nov 2020 Development Center for Biotechnology out-licenses DCB 0703, before November 2020 (Development Center for Biotechnology pipeline, November 2020)
- 30 Nov 2020 Phase-II clinical trials in Influenza virus infections (Prevention) in USA (Intranasal) (Development Center for Biotechnology pipeline, November 2020)